Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988471 | 0.67 | DPP4 (0.33) | BUB1 | |
| SCHEMBL13604721 | 0.66 | NSD2 (0.39) | NSD2 | |
| SCHEMBL10548995 | 0.64 | DPP4 (0.32) | BUB1 | |
| SCHEMBL4895681 | 0.63 | ALDH1A1 (0.42) | BUB1NSD2 | |
| SCHEMBL4895686 | 0.63 | ALDH1A1 (0.42) | BUB1NSD2 | |
| SCHEMBL17057353 | 0.63 | CRBN (0.44) | BUB1 | |
| SCHEMBL10856976 | 0.62 | BUB1 (0.33) | BUB1 | |
| SCHEMBL18320389 | 0.61 | BUB1 (0.40) | BUB1 | |
| SCHEMBL10953757 | 0.60 | METAP1 (0.46) | BUB1 | |
| SCHEMBL10734082 | 0.58 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113962-A1 | Condensed Tricyclic Benzimidazoles For the Treatment of Gastrointestinal Disorders | AITANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-20070244154-A1 | Substituted Tricyclic Benzimidazoles | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-1758900-B1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1799681-A1 | CONDENSED TRICYCLIC BENZIMIDAZOLES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Altana Pharma AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| EP-1758900-A1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | Altana Pharma AG (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006037759-A1 | CONDENSED TRICYCLIC BENZIMIDAZOLES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2006-04-13 | — | — | WO | disclosed |
| WO-2005121139-A1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113962-A1 | Condensed Tricyclic Benzimidazoles For the Treatment of Gastrointestinal Disorders | PGC, SI, VIP | BUB1 1014/4885NSD2 2700/4885 |
| US-20070244154-A1 | Substituted Tricyclic Benzimidazoles | VIP, GIPR, SLC10A2 | BUB1 2079/4885NSD2 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.